TAILORx

TAILORx, trial NCT00310180 sponsored by ECOG-ACRIN and the NCI and reported in 2018, showed that most women with the commonest breast cancer can safely skip chemotherapy if the Oncotype DX gene test puts their recurrence risk in the low or intermediate range. Among 6,711 women with HR-positive, HER2-negative, node-negative disease and mid-range scores, endocrine therapy alone was non-inferior to chemotherapy plus endocrine therapy on invasive disease-free survival, although women aged fifty or under with scores of sixteen to twenty-five derived some chemotherapy benefit, and the trial spared chemotherapy for roughly seventy percent of eligible patients worldwide. RxPONDER extended the finding to node-positive postmenopausal women, and whether the age effect reflects ovarian suppression rather than chemotherapy is the open question.